Lord's Mark Industries Limited has achieved a landmark regulatory milestone by securing MHRA registration from the Medicines & Healthcare products Regulatory Agency, London, UK, for its haemodialysis system. According to reports from NDTV Profit and Hindustan Times, this registration covers Renalyx Health Systems Pvt. Ltd. as a manufacturer, with its haemodialysis system for institutional and home use registered under GMDN Code 58131. The company positions this as India's first and the world's first AI-powered dialysis ecosystem to secure such regulatory milestone at this pace, and as the first Indian company to achieve this milestone in the context of the India-UK Free Trade Agreement (FTA). As per Hindustan Times, what began as a Made-in-India medical technology is now stepping onto the global healthcare stage, with the UK emerging as a key market in the company's international expansion roadmap.
Lord's Mark Industries Limited will start exporting its machine to UK and UK-allied countries from early January 2027. The company's proposed international business model extends beyond the sale of dialysis machines, with plans to explore a dual pathway — supplying its Renalyx systems to healthcare providers while also establishing and operating its own dialysis centres. This creates the potential for the company to participate across the renal-care value chain from medical technology and AI-driven clinical intelligence to infrastructure, centre operations and patient care delivery. According to Hindustan Times, the company is looking to build a scalable renal-care ecosystem that can combine technology deployment with managed healthcare delivery, where healthcare institutions could potentially access the company's dialysis technology while Lord's Mark can explore establishing its own centres to deliver technology-enabled dialysis services directly.
The Renalyx platform has been positioned as an indigenous smart haemodialysis system developed in India, with the broader ecosystem integrating the machine with RenalOS, an AI-powered clinical intelligence platform. The technology combines AI clinical intelligence, operational delivery and remote patient monitoring through the RenalOS platform, which enables AI-led monitoring and supports the identification of early warning signals. Unlike conventional dialysis models, the Lord's Mark ecosystem operates as a connected, intelligence-led renal-care platform that extends care beyond the dialysis session. As per Hindustan Times, the larger vision behind Renalyx is to move dialysis from a machine-centric model towards an intelligence-driven care ecosystem, with the technology designed to enable real-time monitoring of treatment parameters, generate predictive alerts and provide data-driven decision support during dialysis sessions. The ecosystem combines AI clinical intelligence, operational delivery and remote patient monitoring through connected technology that can extend monitoring and continuity of care beyond the dialysis centre.
Dr. Sachidanand Upadhyay, Managing Director & CEO, Lord's Mark Industries Limited, stated that this milestone validates the company's vision around Indian medical technology. According to Hindustan Times, this is more than a regulatory milestone for the company, it is a moment that validates the larger vision they have been building around Indian medical technology. The MHRA registration provides an important platform to explore the UK and UK-allied markets, where the company sees significant potential for both technology deployment and its own dialysis-centre operations. The company's ambition is to make Renalyx a globally recognised Indian healthcare innovation and demonstrate that world-class medical technology can be conceived, engineered and scaled from India. As per Hindustan Times, the company started with a simple but powerful belief — that the next generation of healthcare innovation can be built in India and taken to the world, and with their AI-powered dialysis ecosystem, they are not merely taking a machine into an international market; they are taking an entirely new approach to how renal care can be connected, intelligent and scalable.
This development carries significance for India's med-tech sector as healthcare increasingly moves towards AI-enabled and connected systems. The MHRA communication confirms that Renalyx Health Systems Pvt. Ltd. is registered as a manufacturer and that the haemodialysis system for institutional/home use is registered. However, the MHRA expressly clarifies that this registration does not itself constitute accreditation, certification or approval by the UK Competent Authority. For Lord's Mark Industries, the registration marks the beginning of its next ambition to take an AI-powered Indian dialysis innovation beyond borders and build a global footprint around smarter, connected and scalable renal care. As per Hindustan Times, this development is being positioned as a globalisation journey for an Indian-built healthcare technology platform — taking the company from an indigenous dialysis innovation to an international renal-care business, with the convergence of AI, connected medical devices, cloud technology and clinical intelligence at the heart of the company's vision to create a new generation of renal-care infrastructure.
